Sentence examples for novel trail from inspiring English sources

In a next step, we investigated the effect of CRN5 on TRAIL (TNF-Related Apoptosis-Inducing Ligand -induced ceLigand -inducedprevious study had identified PRMT5 as a novel TRAIL recellor-bindeathprotein, whose knock-down restored the sensitivity of severas tumour cell lines to TRaIL-induced cell death [ 19].

APDC, YC-1 and MG-132 were confirmed as novel TRAIL sensitizing agents whilst the FDA-approved agent, Bortezomib, demonstrated caspase-8-dependent TRAIL-sensitization at 5 nM.

In this report, we describe the identification of two novel TRAIL splice variants, i.e., TRAIL- β and TRAIL- γ, in non-neoplastic and neoplastic cells.

The novel TRAIL isoforms described in this study show an extensive loss of their extracellular binding domain, which plays a key role for trimeric stability, ligand receptor binding capacity and apoptotic signalling (Pitti et al, 1996; Sheridan et al, 1997; Griffith and Lynch, 1998; Ashkenazi et al, 1999; Bodmer et al, 2000b; Kagawa et al, 2001).

Both Tat-treated monocytes and primary CD4 T cells from HIV-infected patients develop tumor necrosis factor (TNF -related apopTNF -relatedtory protein (TRapoptosisstance, potentinhibitoryugh the proteinion of a novel TRAIL splice varesistanceILshort), which potentiallylly binds throughecepthe (R)2 and productionrofapoptotic TRAIL from signovelg.

To investigate whether the novel TRAIL splice variants are exclusively generated in neoplastic cells, we performed RT PCR with unstimulated and stimulated PBMCs showing that the alternative splice variants TRAIL- β and TRAIL- γ are expressed in non-neoplastic cells as well.

Here, we present a novel TRAIL-based gene therapy for malignant gliomas.

Thus, our cells are a suitable model system for the identification of novel TRAIL-sensitizing agents acting through the caspase-8 axis.

Apart from representing potential therapeutic targets for novel, TRAIL-based therapies, the two TRAIL receptors and their expression pattern may be both prognostic and predictive for patient survival.

We have described the characterization of a downstream modification of the novel TRAIL-based drug platform TR3 which has many highly desirable anticancer properties.

We recently developed the novel TRAIL-based drug platform TR3, a genetically fused trimer with the capacity for further molecular modifications such as the addition of tumor-directed targeting moieties.